Quantum Surgical makes its first surgical robot sale in the U.S.

Listen to this article

The Epione surgical robot system. | Source: Quantum Surgical

Surgical robots are increasingly able to reach areas and treat conditions that were previously impossible. Quantum Surgical SAS said it has made the first sale of its Epione surgical robot platform in the U.S. Epione is designed to treat inoperable tumors in the abdomen, including the liver, kidney, and pancreas.

“The entire Quantum Surgical team is thrilled about this first acquisition in the United States,” said Bertin Nahum, co-founder and president of Quantum Surgical, in a release. “Patient treatment and customer satisfaction are our priorities, and we are very proud of the positive feedback we’ve received from our users, which will help accelerate Epione’s adoption in the U.S. territory.”

Founded in 2017, Quantum Surgical said the Epione robotic percutaneous ablation platform is dedicated to the curative and early treatment of cancers. By standardizing access to care, more patients can benefit from innovative, better targeted, and less invasive treatments, asserted the Montpellier, France-based company.

Epione designed to treat inoperable tumors

Epione uses a robotic arm, a navigation system, and a camera. The system inserts a needle through the skin to the tumor and destroys it.

The system enables the early and minimally invasive treatment of abdominal tumors, the company said. The surgical robot allows clinicians to treat inoperable tumors, including those that are difficult to reach because of their to size or location.

Surgeons have already used Epione to treat more than 300 patients worldwide, said Quantum Surgical. The company won the Prix Galien USA in 2022, which it said is equivalent to the Nobel Prize for biopharmaceutical research.

This year, it joined French Tech 2030, a government program intended to encourage innovation in that nation.

Miami center home of first Quantum Surgical U.S. unit

Popular Equipment Finance, a leader in equipment financing that does business as K2 Capital Group, acquired its first Epione robot in the U.S. It works with healthcare organizations across the U.S., including the Miami Cardiac & Vascular Institute, a cancer center that used Epione in May 2023.

That cancer center has now entered into a lease with K2 for the Epione system, Quantum Surgical announced last week.

Epione recently received clearance to treat lung conditions in addition to the liver, kidney, and pancreas. The system is CE-marked for Europe for abdomen and lung tumors, and the U.S. Food and Drug Administration (FDA) has granted clearance for abdominal tumors. 

The global market for surgical robotics could experience a compound annual growth rate of 15.7% from $6.2 billion in 2022 to $25.7 billion by 2032, according to Market.us. The research firm said the North American market had the largest share at 51% in 2022.

Similarly, Precedence Research predicted a 16.4% CAGR, from $8 billion in 2022 to $36.37 billion by 2032, and it also cited the North American market. Maximize Market Research Pvt. Ltd. said that demand and increasing capabilities will help serve North American, Asia-Pacific, and global demand, as revenue grows from $71.94 billion in 2022 to $124.18 billion by 2029 at 8.11%.

Editor’s note: This article was syndicated from MassDevice, a sibling site to The Robot Report.